Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05104463 · ClinicalTrials.gov registry record · Phase 2
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
A Phase 2 study of Mild Cognitive Impairment and Dementia, sponsored by CuraSen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 15
- Study locations
NCT05104463 is a Phase 2 study of Mild Cognitive Impairment and Dementia that has completed, run by CuraSen Therapeutics. The registered enrollment target is 64 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT05104463, a Phase 2 study of Mild Cognitive Impairment and Dementia, has completed, sponsored by CuraSen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
Conditions Studied
Interventions
- DRUG CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Study Locations (15)
Florida
- CuraSen Investigational Site - Boca Raton
- CuraSen Investigational Site - Bradenton
- CuraSen Investigational Site - Lady Lake
- CuraSen Investigational Site - Miami
- CuraSen Investigational Site - New Port Richey
- CuraSen Investigational Site - Winter Park
Texas
- CuraSen Investigational Site - Houston
- CuraSen Investigational Site - Round Rock
- CuraSen Investigational Site - Stafford
Arizona
- CuraSen Investigational Site - Scottsdale
California
- CuraSen Investigational Site - Lafayette
New York
- CuraSen Investigational Site - New York
Ohio
- CuraSen Investigational Site - Cincinnati
Utah
- CuraSen Investigational Site - Salt Lake City
Other
- CuraSen Investigational Site - Christchurch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05104463
The ClinicalTrials.gov registry entry for NCT05104463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The listed sponsor is CuraSen Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 is the first listed.
NCT05104463 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05104463 about?
NCT05104463 is a clinical study titled "A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease". This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
What is the current status of trial NCT05104463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2022-04-11. Estimated completion is 2024-02-01.
What conditions does trial NCT05104463 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT05104463?
The interventions under investigation include: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 (DRUG).
Who is sponsoring clinical trial NCT05104463?
This trial is sponsored by CuraSen Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05104463 being conducted?
This trial has 15 study locations across Arizona, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.